Pfizer Invites the Public to Listen to the Webcast of Pfizer’s Healthcare Conference

NEW YORK, June 03, 2024–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of an interview with Albert Bourla, Chairman and Chief Executive Officer, Goldman Sachs 45.^th Annual World Health Assembly on Monday, June 10, 2024 at 11:20 am Eastern Daylight Time.

To listen to the webcast, visit our website at www.pfizer.com/investors. Information on how to access and register for the webcast will be available at www.pfizer.com/investors beginning today.

A transcript and web replay of the interview will be available on our website at www.pfizer.com/investors within 24 hours of the end of the interview, and will be available for at least 90 days.

About Pfizer: Innovations That Change Patients’ Lives
At Pfizer, we use our world-class technologies and resources to bring treatments to people that significantly extend and improve their lives. We strive to set standards of quality, safety and quality in the discovery, development and production of health products, including new medicines and vaccines. Every day, Pfizer colleagues work in developed and emerging markets to advance health, prevention, treatment and cures for the most feared diseases of our time. In line with our responsibility as one of the world’s leading biopharmaceutical companies, we partner with healthcare providers, governments and local communities to support and expand access to healthcare. Reliable, affordable health care around the world. For 175 years, we have worked to make a difference to all those who rely on us. We regularly post information that may be important to investors on our website at www.Pfizer.com. Additionally, to learn more, please visit us at www.Pfizer.com and follow us on X at @Pfizer and @Pfizer NewsLinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Press Release: Webcasts may include, among others, expectations of our product pipeline, online products and product candidates, including expected regulatory submissions, data analytics, study initiation, approval, initiation, clinical trial results and more. developing data, capital contribution and estimates, potential prices and returns, potential market forces, size and consumption rates, growth, performance, option period and potential benefits ; our expected operating and financial performance, including financial guidance and forecasts; restructuring, business plans, strategy and prospects; policy reviews; budget allocation plans; plans and expectations for our acquisitions, methods and other business development activities, and our ability to successfully exploit these opportunities; production and distribution of products; our efforts to respond to COVID-19, including our COVID-19 products our expectations regarding the impact of COVID-19 on our business, operations and financial results; and other statements about our business, operations and financial results, which are subject to significant risks and uncertainties that could cause actual results to differ from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including sections “Risk Factors” and “Information and Factors That May Affect Future Results”, as well as in subsequent reports on Form 8-K, all of which have been filed with the US Securities and Exchange Commission and are available at www.sec.gov and www.pfizer.com.

The story continues

Statements focusing on the webcast refer only to the first day of the webcast. Pfizer undertakes no obligation to update any forward-looking statements contained on the website as a result of new information or future events or developments.

Category: Finance

Check out the source version at businesswire.com: https://www.businesswire.com/news/home/20240603719406/en/

Names

Media:
PfizerMediaRelations@Pfizer.com
+1 (212) 733-1226

Investor Relations:
IR@Pfizer.com
+1 (212) 733-4848